Chapter 35
Hepatitis and Hemophilia
Mike Makris,
Geoffrey Dusheiko,
Mike Makris
Department of Cardiovascular Science, University of Sheffield, Sheffield, UK
Search for more papers by this authorGeoffrey Dusheiko
UCL Institute for Liver and Digestive Health, Royal Free Hospital, London, UK
Search for more papers by this authorMike Makris,
Geoffrey Dusheiko,
Mike Makris
Department of Cardiovascular Science, University of Sheffield, Sheffield, UK
Search for more papers by this authorGeoffrey Dusheiko
UCL Institute for Liver and Digestive Health, Royal Free Hospital, London, UK
Search for more papers by this authorBook Editor(s):Howard C. Thomas BSc, PhD, FRCP, FRCPath, FMedSci,
Anna S.F. Lok MD,
Stephen A. Locarnini MBBS, BSc(Hons), PhD, FRCPath,
Arie J. Zuckerman MD, DSc, FRCP, FRCPath, FMedSci,
Howard C. Thomas BSc, PhD, FRCP, FRCPath, FMedSci
Emeritus Professor of Hepatology, Department of Medicine, Imperial College London, London, UK
Search for more papers by this authorAnna S.F. Lok MD
Alice Lohrman Andrews Research Professor in Hepatology, Director of Clinical Hepatology, Professor of Internal Medicine, Associate Chair for Clinical Research, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, USA
Search for more papers by this authorStephen A. Locarnini MBBS, BSc(Hons), PhD, FRCPath
Head, Research & Molecular Development, Victorian Infectious Diseases Reference Laboratory, Melbourne, VIC, Australia
Search for more papers by this authorArie J. Zuckerman MD, DSc, FRCP, FRCPath, FMedSci
Emeritus Professor of Medical Microbiology, Formerly Principal and Dean, Royal Free Hospital School of Medicine
Search for more papers by this authorFirst published: 26 July 2013
Summary
Patients with hemophilia A and B are deficient of coagulation factors VIII and IX, respectively, and suffer from spontaneous and traumatic bleeds as a result. Treatment is with intravenous replacement of these factors, which until recently were prepared from thousands of plasma donations. Many patients treated prior to the introduction of viral inactivation in 1985 were infected with hepatitis B, hepatitis C, and HIV. Virtually 100% of individuals exposed to nonvirally inactivated clotting factors have been infected with hepatitis C, of whom 80–85% are chronically infected. Response to treatment and progression to end-stage liver disease in patients with hemophilia are similar as for HCV-positive individuals in the general population infected for a similar length of time.
References
- Mannucci PM, Tuddenham EG. The hemophilias – from royal genes to gene therapy. N Engl J Med 2001; 344: 1773–1779.
- Larsson SA. Life expectancy of Swedish haemophiliacs, 1831–1980. Br J Haematol 1985; 59: 593–602.
- Darby SC, et al. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood 2007; 110: 815–825.
- Makris M, et al. The natural history of chronic hepatitis C in haemophiliacs. Br J Haematol 1996; 94: 746–752.
- Mannucci PM. Outbreak of hepatitis A among Italian patients with haemophilia. Lancet 1992; 339: 819.
- Fletcher ML, et al. Non-A non-B hepatitis after transfusion of factor VIII in infrequently treated patients. Br Med J (Clin Res Ed) 1983; 287: 1754–1757.
- Kernoff PB, et al. High risk of non-A non-B hepatitis after a first exposure to volunteer or commercial clotting factor concentrates: effects of prophylactic immune serum globulin. Br J Haematol 1985; 60: 469–479.
- Makris M, et al. Hepatitis C antibody and chronic liver disease in haemophilia. Lancet 1990; 335: 1117–1179.
- Franchini M. Hepatitis C in haemophiliacs. Thromb Haemost 2004; 92: 1259–1268.
- Troisi CL, et al. A multicenter study of viral hepatitis in a United States hemophilic population. Blood 1993; 81: 412–418.
- Rizzetto M, et al. Delta infection and liver disease in hemophilic carriers of hepatitis B surface antigen. J Infect Dis 1982; 145: 18–22.
- Rosina F, Saracco G, Rizzetto M. Risk of post-transfusion infection with the hepatitis delta virus. A multicenter study. N Engl J Med 1985; 312: 1488–1491.
- Makris M, Conlon CP, Watson HG. Immunization of patients with bleeding disorders. Haemophilia 2003; 9: 541–546.
- Wilde JT, et al. UKHCDO guidelines on the management of HCV in patients with hereditary bleeding disorders 2011. Haemophilia 2011; 17: e877–e883.
- Preston FE, et al. Percutaneous liver biopsy and chronic liver disease in haemophiliacs. Lancet 1978; 2: 592–594.
- Stevens RF, et al. Liver disease in haemophiliacs: an overstated problem? Br J Haematol 1983; 55: 649–655.
- Aledort LM, et al. A study of liver biopsies and liver disease among hemophiliacs. Blood 1985; 66: 367–372.
- Theodore D, et al. Liver biopsy in patients with inherited disorders of coagulation and chronic hepatitis C. Haemophilia 2004; 10: 413–421.
- Shin JL, et al. A Canadian multicenter retrospective study evaluating transjugular liver biopsy in patients with congenital bleeding disorders and hepatitis C: is it safe and useful? Am J Hematol 2005; 78: 85–93.
- Sterling RK, et al. Percutaneous liver biopsy in adult haemophiliacs with hepatitis C virus: safety of outpatient procedure and impact of human immunodeficiency virus coinfection on the spectrum of liver disease. Haemophilia 2007; 13: 164–171.
- Detrait M, et al. Feasibility, safety and cost-effectiveness of transjugular liver biopsy following major surgery in patients with haemophilia. Haemophilia 2007; 13: 588–592.
- Maor Y, et al. Non-invasive biomarkers of liver fibrosis in haemophilia patients with hepatitis C: can you avoid liver biopsy? Haemophilia 2006; 12: 372–379.
- Posthouwer D, et al. Significant liver damage in patients with bleeding disorders and chronic hepatitis C: non-invasive assessment of liver fibrosis using transient elastography. J Thromb Haemost 2007; 5: 25–30.
- Moessner BK, et al. Previously unrecognized advanced liver disease unveiled by transient elastography in patients with haemophilia and chronic hepatitis C. Haemophilia 2011; 17: 938–943.
- Maor Y, et al. Fibrotest or Fibroscan for evaluation of liver fibrosis in haemophilia patients infected with hepatitis C. Haemophilia 2010; 16: 148–154.
- Castera L, Pinzani M, Bosch J. Non invasive evaluation of portal hypertension using transient elastography. J Hepatol 2012; 56: 696–703.
- Kitson M, et al. The prevalence of significant liver fibrosis and cirrhosis in haemophilia patients infected with hepatitis C using FibroScan. Haemophilia 2011; 17: 316–317.
- Posthouwer D, et al. Progression to end-stage liver disease in patients with inherited bleeding disorders and hepatitis C: an international, multicenter cohort study. Blood 2007; 109: 3667–3671.
- Darby SC, et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors’ Organisation. Lancet 1997; 350: 1425–1431.
- Tagliaferri A, et al. Mortality and causes of death in Italian persons with haemophilia, 1990–2007. Haemophilia 2010; 16: 437–446.
- Lok AS, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009; 136: 138–148.
- Tradati F, et al. A prospective multicenter study of hepatocellular carcinoma in italian hemophiliacs with chronic hepatitis C. The Study Group of the Association of Italian Hemophilia Centers. Blood 1998; 91: 1173–1177.
- Santagostino E, et al. A 6-month versus a 12-month surveillance for hepatocellular carcinoma in 559 hemophiliacs infected with the hepatitis C virus. Blood 2003; 102: 78–82.
- Ghany MG, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335–1374.
- Meijer K, Haagsma EB. HCV-related liver cancer in people with haemophilia. Haemophilia 2012; 18: 17–24.
- Makris M, et al. A randomized controlled trial of recombinant interferon-alpha in chronic hepatitis C in hemophiliacs. Blood 1991; 78: 1672–1677.
- Posthouwer D, et al. Treatment of chronic hepatitis C in patients with haemophilia: a review of the literature. Haemophilia 2006; 12: 473–478.
- Posthouwer D, et al. Antiviral therapy for chronic hepatitis C in patients with inherited bleeding disorders: an international, multicenter cohort study. J Thromb Haemost 2007; 5: 1624–1629.
- Alavian SM, et al. Peginterferon alpha-2a and ribavirin treatment of patients with haemophilia and hepatitis C virus infection: a single-centre study of 367 cases. Liver Int 2010; 30: 1173–1180.
- Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997; 26(3 Suppl 1): 112S–121S.
- Ge D, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399–401.
- Bruno S, et al. Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. Hepatology 2010; 51: 388–397.
- McHutchison JG, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580–593.
- Naing C, et al. Relationship between hepatitis C virus infection and type 2 diabetes mellitus: meta-analysis. World J Gastroenterol 2012; 18: 1642–1651.
- Rasmussen AL, et al. Chronic immune activation is a distinguishing feature of liver and PBMC gene signatures from HCV/HIV coinfected patients and may contribute to hepatic fibrogenesis. Virology 2012; 430: 43–52.
- Ragni MV, Belle SH. Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection. J Infect Dis 2001; 183: 1112–1125.
- Jacobson IM, et al. A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C. J Viral Hepat 2012; 19(Suppl 2): 1–26.
- Pawlotsky JM. New antiviral agents for hepatitis C. F1000 Biol Rep 2012; 4: 5.
- Marchioro TL, et al. Hemophilia: role of organ homografts. Science 1969; 163: 188–190.
- Lewis JH, et al. Liver transplantation in a hemophiliac. N Engl J Med 1985; 312: 1189–1190.
- Lambing A, Kuriakose P, Kachalsky E. Liver transplantation in the haemophilia patient. Haemophilia 2012; 18: 300–303.
- Eguchi S, et al. Liver transplantation for patients with human immunodeficiency virus and hepatitis C virus coinfection with special reference to hemophiliac recipients in Japan. Surg Today 2011; 41: 1325–1331.
- Horton S, et al. Re-emergence of a low-titre factor VIII inhibitor after liver transplant. Haemophilia 2012; 18: e69–e71.
